|
|
|
| Visual analysis of traditional Chinese medicine application in pancreatic cancer treatment based on CiteSpace |
| ZHANG Dingdan TIAN Shaodan LYU Liyuan LUO Mei MIAO Lu |
| Department of Hematology and Oncology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China |
|
|
|
|
Abstract Objective To explore the visual analysis of traditional Chinese medicine application in pancreatic cancer treatment based on CiteSpace. Methods Literatures related to the treatment of pancreatic cancer by traditional Chinese medicine collected in CNKI and Web of Science databases from January 2000 to December 2021 were searched by computer, and the author, institution, keyword co-occurrence, clustering, and emergence of this study were mapped and analyzed by using CiteSpace software. Results A total of 614 papers were included in the study, and the overall number of papers was on the rise, with 23 core authors, the largest number of papers was published by Fudan University. The keyword clustering graph showed that the current hot spots were mainly concentrated in traditional Chinese medicine syndrome differentiation and treatment, traditional Chinese medicine clinical research and mechanism of action, cell research, and other aspects. Conclusion The research heat of traditional Chinese medicine treatment of pancreatic cancer is increasing, and the research focus is gradually shifting to traditional Chinese medicine clinical observation and mechanism research. It is suggested to strengthen the connection between basic research and clinical practice, focus on transformation research, and fully explore the therapeutic value of traditional Chinese medicine.
|
|
|
|
|
|
[1] Klein AP. Pancreatic cancer epidemiology：understanding the role of lifestyle and inherited risk factors [J]. Nat Rev Gastroenterol Hepatol，2021，18（7）：493-502.
[2] Mcguigan A，Kelly P，Turkington RC，et al. Pancreatic cancer：A review of clinical diagnosis，epidemiology，treatment and outcomes [J]. World J Gastroenterol，2018，24（43）：4846- 4861.
[3] Zhao C，Gao F，Li Q，et al. The Distributional Characteristic and Growing Trend of Pancreatic Cancer in China [J]. Panc- reas，2019，48（3）：309-314.
[4] 王宁，刘硕，杨雷，等.2018全球癌症统计报告解读[J].肿瘤综合治疗电子杂志，2019，5（1）：87-97.
[5] 冯程程，彭青兰，焦学洋，等.1990—2019年中国胰腺癌发病和死亡情况及其变化趋势分析[J].中国肿瘤，2022， 31（5）：321-326.
[6] Ferlay J，Partensky C，Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017 [J]. Acta Oncol，2016，55（9/10）：1158-1160.
[7] Sung H，Ferlay J，Siegel RL，et al. Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin，2021，71（3）：209-249.
[8] 高俊宽.文献计量学方法在科学评价中的应用探讨[J].图书情报知识，2005（2）：14-17.
[9] 周杰.基于miR-21对胰腺星状细胞EMT的影响探讨华蟾素改善胰腺癌微环境的机制[D].北京：北京中医药大学，2020.
[10] Li W，Chen Z，Gong FR，et al. Growth of the pancreatic can- cer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway [J]. Eur J Cancer，2011，47（17）：2654- 2664.
[11] Wang KP，Miao XY，Kong FH，et al. Integrating Network Pharmacology and Experimental Verification to Explore the Mechanism of Effect of Zuojin Pills in Pancreatic Cancer Treatment [J]. Drug Des Dev Ther，2021，15：3749-3764.
[12] 宋利斌，刘鲁明，陈颢，等.清胰化积方化裁联合西药治疗232例胰腺癌术后患者回顾性研究[J].中国中西医结合杂志，2018，38（8）：932-935.
[13] 李娜，富琦，张青.郁仁存治疗胰腺癌经验[J].中医杂志，2015，56（20）：1725-1727.
[14] 张娟，王鹏，刘鲁明.胰腺癌中医证候分析[J].中华中医药杂志，2012，27（3）：579-581.
[15] 李惠，沈凯凯.中药抗肿瘤联合用药研究进展[J].上海中医药大学学报，2017，31（3）：90-94.
[16] 黄霜霜，朱佳敏，赵鹏，等.中药联合化疗对晚期胰腺癌的临床疗效及安全性研究[J].浙江医学，2019，41（21）：2316-2318，2327.
[17] 程雄涛，曹建雄.中药联合化疗治疗胰腺癌疗效的Meta分析[J].湖南中医杂志，2020，36（9）：140-144.
[18] 张惠子，黄金昶.加味乌梅丸联合吉西他滨对胰腺癌移植瘤的抑制及细胞凋亡的实验研究[J].环球中医药，2018，11（7）：991-995.
[19] 黄霜霜.康莱特注射液联合化疗治疗晚期脾虚气滞型胰腺癌的疗效分析[D].杭州：浙江中医药大学，2019.
[20] Liu YH，Shi CJ，He Z，et al. Inhibition of PI3K/AKT sign- aling via ROS regulation is involved in Rhein-induced apo- ptosis and enhancement of oxaliplatin sensitivity in pancreatic cancer cells [J]. Int J Biol Sci，2021，17（2）：589-602.
[21] Yao LC，Wu L，Wang W，et al. Panax Notoginseng Saponins Promote Cell Death and Chemosensitivity in Pancreatic Cancer through the Apoptosis and Autophagy Pathways [J]. Anti-Cancer Agents Med Chem，2021，21（13）：1680-1688.
[22] Yang HT，Tong Z，Shen L，et al. Brucea javanica Increases Survival and Enhances Gemcitabine Efficacy in a Patient-derived Orthotopic Xenograft （PDOX） Mouse Model of Pancreatic Cancer [J]. Anticancer Res，2020，40（9）：4969- 4978.
[23] Wang BL，Shen C，Li Y，et al. Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling [J]. OncoTargets Ther，2019， 12：5751-5765.
[24] 徐光星，何若苹.国医大师何任学术思想浅析—基于不同主症的胰腺癌辨治经验[J].浙江中医药大学学报，2019，43（10）：1019-1023，1029.
[25] 张维新，王晶超.中医针灸对缓解胰腺癌患者疼痛及抑郁症的效果研究[J].世界最新医学信息文摘，2015，15（A1）：29-30.
[26] 丁云晴.电针促进阳虚型胃癌及胰腺癌术后康复的临床研究[D].沈阳：辽宁中医药大学，2021.
[27] 刘槟，吴超勇，张培彤.胰腺癌湿证量化诊断标准探索性研究[J].中华中医药杂志，2021，36（11）：6778-6781. |
|
|
|
